ArticleJournal of psychopharmacology (Oxford, England)2018
Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
Article in Journal of psychopharmacology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.Drugs & aging · 2026Pooled it
- Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report.British journal of clinical pharmacology · 2019Pooled it
- Standardizing care for agitation in Alzheimer's disease, results from a randomized controlled trial of an integrated care pathway versus usual care - the StaN trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- [Benefits and risks of gabapentinoids in geriatric psychiatry].Der Nervenarzt · 2026Review
- Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment.ACS omega · 2026Article
- Behavioral symptoms of dementia and psychotropic use during the COVID-19 pandemic.Frontiers in epidemiology · 2026Article
- Agitation in Alzheimer's disease: From assessment to therapeutics.World journal of psychiatry · 2025Review
- The Canadian Coalition for Seniors' Mental Health Canadian Clinical Practice Guidelines for Assessing and Managing Behavioural and Psychological Symptoms of Dementia (BPSD).Canadian geriatrics journal : CGJ · 2025Article
- Impact of healthcare system strain on the implementation of ICU sedation practices and encephalopathy burden during the early COVID-19 pandemic.GeroScience · 2025Article
- Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease.CNS drugs · 2025Review
- Challenges in the management of visual and tactile hallucinations in elderly people.World journal of psychiatry · 2025Article
- A Comprehensive Understanding of Psychomotor Agitation: From Causes to Hospital Care.Current neuropharmacology · 2025Review
- Factors associated with cognitive function in patient with Alzheimer's disease with newly prescribed acetylcholinesterase inhibitors: A 1-year retrospective cohort study.Aging medicine (Milton (N.S.W)) · 2024Article
- Barriers and facilitators to care for agitation and/or aggression among persons living with dementia in long-term care.BMC geriatrics · 2024Article
- Bibliometric Analysis of the Research Status and Global Trends in Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease from 2002 to 2022.Current neuropharmacology · 2024Article
- Disparities by Socioeconomic Status and Diagnosis of Dementia in the Prescribing of Antipsychotics in a Real-World Data Population Over 60 Years of Age.Journal of Alzheimer's disease : JAD · 2024Observational
- Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management.Arquivos de neuro-psiquiatria · 2023Article
- G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.Signal transduction and targeted therapy · 2023Review
- Neuropsychiatric Symptom Burden across Neurodegenerative Disorders and its Association with Function.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Article
- Long-Stay Mood Stabilizer Use Increasing as Prescription of Antipsychotics Decreases.GeroPsych · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBehavioural and psychological symptoms of dementia (BPSD) include agitation and aggression in people with dementia. BPSD is common on inpatient psychogeriatric units and may prevent individuals from living at home or in residential/nursing home settings. Several drugs and non-pharmacological treatments have been shown to be effective in reducing behavioural and psychological symptoms of dementia. Algorithmic treatment may address the challenge of synthesizing this evidence-based knowledge.
methodsA multidisciplinary team created evidence-based algorithms for the treatment of behavioural and psychological symptoms of dementia. We present drug treatment algorithms for agitation and aggression associated with Alzheimer's and mixed Alzheimer's/vascular dementia. Drugs were appraised by psychiatrists based on strength of evidence of efficacy, time to onset of clinical effect, tolerability, ease of use, and efficacy for indications other than behavioural and psychological symptoms of dementia.
resultsAfter baseline assessment and discontinuation of potentially exacerbating medications, sequential trials are recommended with risperidone, aripiprazole or quetiapine, carbamazepine, citalopram, gabapentin, and prazosin. Titration schedules are proposed, with adjustments for frailty. Additional guidance is given on use of electroconvulsive therapy, optimization of existing cholinesterase inhibitors/memantine, and use of pro re nata medications.
conclusionThis algorithm-based approach for drug treatment of agitation/aggression in Alzheimer's/mixed dementia has been implemented in several Canadian Hospital Inpatient Units. Impact should be assessed in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.